Skip to content Provide accessibility feedback
By using the Volpara website you accept our use of cookies. Here’s our privacy statement.
Breast Health
For Patients
Science
Contact us
Magnifying glass Search

Microsoft and Volpara Health join forces to accelerate the research and development of software that uses mammograms to identify potential cardiovascular issues

Volpara Health – Published on July 18, 2022

Highlights:

  • Heart disease is the leading cause of death of US women
  • Breast arterial calcifications* have been shown to be associated with
    cardiovascular disease outcomes1
  • The collaboration’s intent is to expand breast cancer screening programs’ ability
    to make cardiovascular assessments from routine mammograms
  • Microsoft, based in Redmond, WA, USA, are leaders in the development of
    personal computer software systems, applications, and cloud services
  • Volpara Health, based in Wellington, NZ, are leaders in artificial intelligence for
    breast cancer detection and risk assessment

Wellington, NZ, 21 June 2022: Volpara Health Technologies (“Volpara,” “the Group,” or “the Company”; ASX:VHT), a global health technology software leader providing an integrated platform for personalised breast care, today announced a new research and development collaboration with Microsoft to accelerate the creation of a product that detects and quantifies breast arterial calcifications (BACs).

Microsoft and Volpara share a commitment to improving women’s health through science and innovation. The product will build upon Volpara’s approach to quantitative and objective breast density scoring using artificial intelligence (AI). Capitalising upon Volpara’s recent BAC patent, the product will create a tissue composition map that identifies and quantifies BACs from a mammogram, helping radiologists identify the need to take steps toward prevention of heart disease. Machine learning and AI specialists from Microsoft will assist with improving Volpara’s BACs model and data processing, while Microsoft engineers will collaborate with the Volpara team on the product’s technical development and operationalisation.

This project is an expansion of the companies’ relationship over the last decade. Last year, Volpara’s innovative work in supporting healthcare providers was recognised with its SaaS (Software as a Service) Award win at the Microsoft New Zealand Partner Awards. Microsoft SaaS and cloud products have played a fundamental role in supporting Volpara’s development of the latest, FDA-cleared version of their core AI algorithm. To date, the algorithm has been used to assess the breast composition of more than 14.5M women through Volpara’s analysis of over 60M mammography and tomosynthesis images. These images, representing one of the world’s largest de-identified image datasets, will prove a pivotal resource for the BACs project.

The BACs product, as a cardiac decision-support tool for radiologists, would mark Volpara’s entrance into a new area of care, part of a US$146.4B2 cardiovascular disease market. With access to over 35 percent of the US breast screening market, Volpara has the installation base to facilitate rollout and adoption of the product, creating a new revenue stream. For women, the BACs product would add a new dimension to their regular breast screenings, providing important information about their cardiovascular health. Any significant BACs findings could be delivered through the Volpara® Breast Health Platform™ directly to the healthcare provider or through Volpara’s partner network.

Recently, Volpara announced Teri Thomas as the new Chief Executive Officer, with cofounder and former CEO Ralph Highnam, PhD, transitioning to Chief Science and Innovation Officer. As part of his new role, Highnam will spearhead the BAC initiative.

Of the joint project Highnam said: “The trusted relationship we have built with Microsoft over the years is important to Volpara’s future, especially our utilisation of the powerful Azure Cloud platform for machine learning and product development. Our mission and vision around the future of healthcare align well with Microsoft’s. Though we are in the early stages of BAC product development, this collaboration will accelerate our efforts as we advance science together.”

“With one in three deaths in New Zealand caused by cardiovascular disease, this new research and development collaboration means that, together, we can detect and identify earlier symptoms of heart disease in women,” said Microsoft New Zealand Partner Lead, Matt Bostwick. “Volpara’s innovation with AI is not only improving healthcare across the globe, but it has the potential to save millions of lives. This is true AI for Good.”

*Breast arterial calcifications are clusters and patterns of calcification that appear on the mammogram image and may indicate heart disease or high risk of disease.

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386618/#:~:text=Conclusions,and%20inversely
%20associated%20with%20smoking.
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370385/#:~:text=The%20cardiovascular%20dise
ase%20market%2C%20which%20includes%20hypertension%2C%20dyslipidaemia,1.8%25%2C
%20according%20to%20business%20intelligence%20provider%20GBI%20Research.

Authorisation & Additional Information
This announcement was authorised by the CEO of Volpara Health Technologies Limited.
ENDS

For further information, please contact:
Teri Thomas
Chief Executive Officer Director
Volpara Health Technologies
teri.thomas@volparahealth.com
t: +64 4 499 6029

Hannah Howlett
Investor Relations
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)
VHT is a health technology software company founded in 2009 on research originally conducted at the University of Oxford. VHT’s clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its mammography practice-management software helps with productivity, compliance, reimbursement, and patient tracking. VHT’s technology and services have been used by customers and/or research projects in 40 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A$132 million, including A$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand. For more information, visit www.volparahealth.com.

About Microsoft Corp (Nasdaq “MSFT” @microsoft)
Microsoft enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organisation on the planet to achieve more. For more information, visit www.microsoft.com.